Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive, PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.